Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting Ambit Biosciences Corporation announced today that you will see multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Conference to be held in New Orleans, LA ,5-8 December, 2009. An oral display will highlight outcomes from an ongoing clinical Phase I monotherapy safety study in adults with severe myeloid leukemia levitrainorge.com http://levitrainorge.com . Additionally, non-clinical data will be presented evaluating the effect of AC220 monotherapy and in conjunction with chemotherapy. AML continues to be a disease with a substantial unmet medical need and brand-new therapies are urgently needed, said M.